RxDoctor Payments Data

Ashley Broce

Internal Medicine · Joplin, MONPI 1508200510

Payments from drug & device makers

$796in general payments, 2019–2025

Across 42 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$153
  • Exact Sciences$137
  • Lilly USA, LLC$98
  • Amgen$85
  • AstraZeneca$47
  • Idorsia Pharmaceuticals US Inc$31
  • plus $245 from 13 others

What the payments were for

  • Food & beverage$76696%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$796 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$22,910
Medicare patients
136
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$19,900
TrulicityDulaglutide18$18,681
MounjaroTirzepatide11$11,689
EliquisApixaban14$11,558
FarxigaDapagliflozin Propanediol15$10,413
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,112
JanuviaSitagliptin Phosphate12$9,350
SymbicortBudesonide/Formoterol Fumarate12$2,850
Pregabalin58$1,426
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,004
Albuterol Sulfate HfaAlbuterol Sulfate26$736
Gabapentin57$703
Pantoprazole Sodium29$474
Venlafaxine Hcl ErVenlafaxine Hcl15$328
Tramadol Hcl33$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$98$30,37029 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$47$23,37543 claims
Novo NordiskOzempic$18$19,90017 claims
PfizerEliquis$11$11,55814 claims
MerckJanuvia$25$9,35012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →